Cathepsin K has recently been identified at the major cysteine protease expressed in osteoclasts.  The abundance and selective location of cathepsin K in cells responsible for bone resorption has lead to a new interest in design of cathepsin K inhibitors for the treatment of osteoporsis. Increased bone resorption may release factors from the extracellular matrix that contribute to tumor growth.  In fact, recent reports indicate that interactions between prostate cancer cells, osteoblasts, osteoclasts, and bone matrix are essential in the formation of bone metastases. The synthesis and evaluation of new synthetic compounds using cathepsin K is reported. Supported by National Cancer Institute at NIH (Grant No. 3R15CA086933-04 and 3R15CA086933-04A2S1) and Western Illinois University.

New cathepsin K inhibitors containing argininal thiosemicarbazones

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.